Bladder Cancer Can Gain From Sustained-Release Chemotherapy

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Merck to Acquire Verona for $10B, COPD Drug in Focus

Merck has pulled off another acquisition that happens to...

PDUFA Crucial for Biopharmaceutical Innovation in the US

The United States happens to lead the world when...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Piramal Pharma Expands Lexington Sterile Injectables Plant

Piramal Pharma has started work on the expansion of...

As reported by a study, a novel, sustained-release chemotherapy delivery device which is inserted in the bladder has gone on to facilitate the tumour response. The treatment was given to patients in the elderly bracket who had advanced bladder cancer and were medically unfit for standard treatment to take place.

TAR-200, the Intravesical device, provides consistent, low-dose, and local delivery of gemcitabine chemotherapy. It is proven to be mostly safe, well tolerated, and to have noteworthy and beneficial effects on the outcome of bladder cancer. The drug delivery device’s objective is to limit the cancer’s growth and progression while also putting a considerable limit on chemotherapy’s toxic effects.

In the phase 1 study, patients with muscle-invasive bladder cancer were analysed; there were 24 men and 11 women, to be precise, with a median age of 84 years. Apparently, all the individuals were suffering from transurethral resection of bladder tumours so as to remove the visible cancer.

Once implanted in the patient, the silicone tube, i.e., the drug delivery device, released gemcitabine over a period of 21 days. Another process was performed to take out and replace the device for a total of four treatments that spanned 84 days.

Notably, 11 out of 35 patients had an absolute tumour response to TAR-200. On follow-up, no evidence of bladder cancer was found in these patients. Another 3 patients happened to have a partial response, with an overall response rate going up to 40%. When considering the median overall survival rate, it came to 37 months. That compared to a 12 total survival rate that was found in previous studies where muscle-invasive bladder cancer did not get the curative-intent treatment.

Of the 14 patients that had lasting responses when it came to the TAR-200 treatment, more than 70% were free from progressive bladder cancer at 12 months after the treatment. The total observed clinical response to TAR-200 was indeed robust as well as durable across patients with curative-limited treatment options that were very limited, as per the authors of the study.

Latest stories

Related stories

Merck to Acquire Verona for $10B, COPD Drug in Focus

Merck has pulled off another acquisition that happens to...

PDUFA Crucial for Biopharmaceutical Innovation in the US

The United States happens to lead the world when...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Piramal Pharma Expands Lexington Sterile Injectables Plant

Piramal Pharma has started work on the expansion of...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back